Mitochondrial peptides: state of the evidence in 2026
The mitochondrial peptide field has matured substantially over the past decade. Three compounds now dominate the literature: Humanin (discovered 2001, encoded in the mitochondrial 16S rRNA gene), MOTS-c (discovered 2015, encoded in the 12S rRNA gene) and SS-31 (synthetic Szeto-Schiller cardiolipin stabiliser, designed in the early 2000s).
All three compounds emerged from a broader reappraisal of mitochondrial biology's role in ageing that has taken hold since the early 2000s: mitochondria are not merely bioenergetic organelles but active signalling hubs, capable of producing peptides from short open reading frames within their own genome (the so-called mitochondrial-derived peptides, or MDPs) that act well beyond the organelle itself. Humanin and MOTS-c are the two best-characterised members of this MDP class, and their discovery reframed the mitochondrial genome as encoding regulatory signals in addition to the respiratory-chain subunits it was long known for.
Humanin's profile is increasingly that of an endocrine mitokine — a peptide released by mitochondria under stress that signals systemically to coordinate cellular and metabolic adaptation. The 2014 Yen et al. paper linking plasma Humanin to longevity in centenarian offspring positioned the peptide squarely within ageing biology, and subsequent work has supported the framing.
Mechanistically, Humanin's best-characterised action is cytoprotective: it binds the extracellular receptor complex formed by CNTFR, WSX-1 and gp130, triggering STAT3 activation in a manner that inhibits neuronal and cardiac apoptosis under metabolic stress. This same receptor pathway is engaged during ischaemic injury, which is part of why Humanin analogues (notably the more stable HNG variant) have drawn interest in cardioprotection and neuroprotection research, alongside the longevity framing established by the centenarian-offspring literature.
MOTS-c has accumulated a coherent body of evidence for its role as an endogenous exercise-mimetic, with the Reynolds et al. 2021 Nature Communications paper providing the most comprehensive demonstration of partial exercise-pathway reproduction in aged muscle. The 2018 Kim et al. demonstration of nuclear translocation and chromatin binding under stress placed MOTS-c among the small set of peptides with documented direct gene-regulatory activity.
MOTS-c's action on AMPK activation and glucose homeostasis has also drawn attention in metabolic-disease research separate from its ageing-biology framing. Lu et al. (2019, Aging Cell) reported that MOTS-c administration attenuated age-dependent and diet-induced insulin resistance in mice, with effects converging on AMPK-mediated regulation of glucose uptake in skeletal muscle. This metabolic angle complements the exercise-mimetic framing and suggests MOTS-c's downstream effects are broader than a single pathway.
SS-31 has the most-developed clinical-translation programme. Phase II and III trials in primary mitochondrial myopathy (MMPOWER), dry AMD (ReCLAIM) and ischaemia-reperfusion contexts have produced mixed efficacy outcomes but a strong human safety dataset. The Siegel et al. 2013 paper demonstrating restoration of aged-muscle physical performance to young-mouse levels within 8 days remains one of the most striking proof-of-mechanism observations in the longevity literature.
The translational gap for all three compounds is similar: robust rodent and cell-culture mechanism data has not yet been matched by large, adequately powered human trials with ageing-relevant endpoints rather than disease-specific ones. SS-31's MMPOWER-3 trial missed its primary endpoint despite the earlier mechanistic promise, a reminder that cardiolipin stabilisation demonstrated in isolated mitochondria does not automatically translate into clinically measurable functional gains in a diseased human population.
Delivery and stability present a further practical barrier specific to this class. Humanin and MOTS-c are both short, unmodified peptides subject to rapid proteolytic degradation in circulation, which complicates dose-response characterisation outside a controlled infusion or injection protocol. SS-31's alternating D-amino-acid and cationic-aromatic motif was specifically engineered to concentrate the peptide in the inner mitochondrial membrane and resist degradation, which is part of why it has progressed furthest in clinical development relative to the two naturally occurring mitokines — engineering for pharmacokinetics, not just potency, has mattered as much as the underlying biology in determining which compound reached the clinic first.
The integrative question for 2026 is whether mitochondrial peptide combinations — signalling mitokines paired with structural stabilisers — produce additive or synergistic effects. The mechanistic case is plausible; clinical data has not yet tested it.